EUVIMEDOpdag EUVIMED
Leserbrief

Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?

Taher Modarressi

Cleveland Clinic Journal of Medicine · 2024

DOI: 10.3949/ccjm.91c.02001 ↗

At a glance

Leserbrief in Cleveland Clinic Journal of Medicine, 2024. Written by Taher Modarressi. Institution: Princeton Cardiometabolic Health, Pennington, NJ. Major MEDLINE topics: Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2. Cited 1 times so far (Crossref).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

To the Editor: The article by Sekerak and colleagues[1][1] is an excellent highlight of the sodium-glucose cotransporter 2 (SGLT-2) inhibitor family’s pluripotent cardiorenal impacts. I offer several suggestions to optimize the utilization of this therapeutic class. First, regarding dosing, while

Subjects

MeSH terms (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsHeart FailureRenal Insufficiency, ChronicDiabetes Mellitus, Type 2HumansHypoglycemic Agents

Substances

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic Agents

Authors and institutions

  • Princeton Cardiometabolic Health, Pennington, NJ.

Cite

APA

Modarressi, T. (2024). Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?. Cleveland Clinic Journal of Medicine. https://doi.org/10.3949/ccjm.91c.02001

Vancouver

Modarressi T. Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?. Cleveland Clinic Journal of Medicine. 2024. doi:10.3949/ccjm.91c.02001

BibTeX
@article{Modarressi2024,
  author = {Modarressi, Taher},
  title = {Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?},
  journal = {Cleveland Clinic Journal of Medicine},
  year = {2024},
  doi = {10.3949/ccjm.91c.02001}
}
Start for free →